After hosting an investor call with rheumatologist/Immunologist Dr. Peter Lipsky, Stifel quotes him as saying that Horizon's Krystexxa, is drastically better than current chronic refractory gout treatments. The drug is able to "easily identify and manage immunogenicity," unlike competing treatments, and it treats the disease more quickly, than existing drugs Stifel quoted Dr. Lipsky as saying. He believes that 200,000-400,000 patients could be treated with the drug, versus the company's initial estimate of about 50000, Stifel reported. The firm keeps a $45 price target and Buy rating on the shares.